April 16, 2016
Kite Pharma Announces Review of National Cancer Institute's Manufacturing Facilities
- Kite's four ongoing multi-center clinical trials of its lead product candidate, KTE-C19, are continuing -
- Kite remains on track to file an investigational new drug application (IND) with the
Kite and the NCI are advancing multiple clinical trials under
review of the NCI's manufacturing facilities is not related to KTE-C19
or Kite's manufacturing capabilities. Kite's four ongoing multi-center
clinical trials of KTE-C19 are continuing. Kite also
remains on track to file an IND with the
Cautionary Note on Forward-Looking Statements
press release contains forward-looking statements for purposes of the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. We may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should" or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other
things: the ability and timing of filing an IND for a TCR-based product
candidate, and the ability and willingness of the NCI to continue
research and development activities pursuant to the CRADAs. Various
factors may cause differences between Kite's expectations and actual
results as discussed in greater detail in Kite's filings with the
Greg MannVP, Investor Relations email@example.com For Media: Justin Jackson Burns McClellan(212) 213-0006 firstname.lastname@example.org
News Provided by Acquire Media